Elanco Animal Health Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Elanco Animal Health Incorporated on July 3, 2024. The filing reports the entry into a material definitive agreement regarding the company's senior secured first lien revolving credit facility.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, or total debt levels. The primary financial metric disclosed relates to the restructuring of the company's revolving credit facility.
Material Changes
On July 3, 2024, the Company entered into Amendment No. 2 to its Credit Agreement. The material changes include:
- Maturity Extension: The maturity date for the Revolving Credit Facility was extended from August 1, 2025, to July 3, 2029.
- Springing Maturity Condition: The new maturity is subject to a springing maturity of 91 days prior to the maturity date of certain long-term indebtedness if the aggregate principal amount of such indebtedness equals or exceeds $400 million (subject to certain exceptions).
- Covenant Adjustments: The amendment included other changes to certain covenants and terms of the agreement.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding future performance. The document references the full text of Amendment No. 2 (Exhibit 10.1) for complete details on covenants and terms. No specific risks or contingencies were detailed in the summary text of this report.
Investor Verification Checklist
- Review Exhibit 10.1 (Amendment No. 2) to understand the specific changes to covenants and terms beyond the maturity extension.
- Verify the current aggregate principal amount of the Company's long-term indebtedness to assess the likelihood of the $400 million springing maturity trigger.
- Confirm the identity of the lenders and agents involved, including JPMorgan Chase Bank, N.A., and Goldman Sachs Bank USA.